| Identification | Back Directory | [Name]
Ganglioside GM3 | [CAS]
124579-05-1 | [Synonyms]
Neu5Aca2,3Galb1,4Glc Ceramide Synonym:GM3
Octadecanamide, N-[(1S,2R,3E)-1-[[[O-(N-acetyl-α-neuraminosyl)-(2→3)-O-β-D-galactopyranosyl-(1→4)-β-D-glucopyranosyl]oxy]methyl]-2-hydroxy-3-heptadecen-1-yl]- | [Molecular Formula]
C59H108N2O21 | [MOL File]
124579-05-1.mol | [Molecular Weight]
1181.51 |
| Chemical Properties | Back Directory | [Boiling point ]
1260.2±65.0 °C(Predicted) | [density ]
1.26±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
1.92±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Ganglioside GM3-d7 is deuterium labeled Ganglioside GM3. Ganglioside GM3 is a precursor of a-, b-, and c-series gangliosides, interacts with transmembrane receptors such as the epidermal growth factor and insulin receptors, and regulates receptor functions by creating a specialized lipid environment. Ganglioside GM3 is synthesized by GM3 synthase and can be used for the research of hypercholesterolemia[1][1][2][3]. | [References]
[1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. DOI:10.1177/1060028018797110
[2] Nihei W, et al. NPC1L1-dependent intestinal cholesterol absorption requires ganglioside GM3 in membrane microdomains. J Lipid Res. 2018 Nov;59(11):2181-2187. DOI:10.1194/jlr.M089201
[3] Inokuchi JI, et al. Pathophysiological Significance of GM3 Ganglioside Molecular Species With a Particular Attention to the Metabolic Syndrome Focusing on Toll-Like Receptor 4 Binding. Front Mol Biosci. 2022 May 30;9:918346. DOI:10.3389/fmolb.2022.918346 |
|
|